Gunderson Dettmer represented client Avoro Ventures as an investor in the $135 million Series B financing of Hemab Therapeutics, a clinical-stage biotechnology company. Hemab develops healthcare technology to provide biotechnology services for preventative treatments and functional cures of underserved bleeding and thrombotic disorders. The company will use the new capital to help grow its business and scientific plans until 2025.

In the announcement of the transaction, CEO and President of Hemab Therapeutics Benny Sorensen said, “Hemab is fundamentally reimagining the treatment paradigm for underserved bleeding and thrombotic disorders. This financing will allow us to progress our clinical programs for the first prophylactic treatments for Glanzmann Thrombasthenia and von Willebrand Disease, delivering functional cures for patients in need. We're grateful for this robust syndicate of investors who support our approach of leveraging validated advanced technologies and deep insights into the biology of clotting to overcome decades of scientific stagnation."

The Gunderson Dettmer deal team was led by Nevin Fox and included Jen Lichtman and Morgan Clarke.

Companies
Avoro Ventures
Hemab Therapeutics